Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Currently, clinical outcomes using chimeric-antigen receptors (CARs) show great promise against hematological malignancies. However, due to the re-emergence of antigen-positive or negative cells, it is common for these CARs to observe relapses after treatment. Therefore, improvements in developing CAR designs that target loss of target antigens and increase the persistence of effector cells represent a critical need.
Dual targeting provides more comprehensive ablation and overcomes the pitfalls of single-antigen therapy by preventing relapses due to antigen loss. Here, Creative Biolabs has developed an innovative anti-tumor activity compound CAR, possessing two complete and independent CAR receptors against two different antigens, thereby addressing a major obstacle to this emerging therapeutic class.
Compound CAR Design
The compound CAR we developed can simultaneously express two scFv anibody domains and target two different tumor antigens. Hence, cCAR includes two discrete CAR units: anti - antigen1 and anti - antigen2 CAR, which linked by a self-cleaving P2A peptide thus expressing both functional CAR molecules on the T-cell surface.
The dual targeting mechanism exhibits potent and specific anti-tumor activity and may increase the persistence of effector cells by preventing relapse due to antigen loss.
Fig.1 Schematic representation of cCAR.
Read more:
www.nature.com/articles/leu2017302
www.nature.com/articles/s41375-018-0075-3
For more detailed information, please feel free to contact us or directly sent us an inquiry.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
